{"id":"W4387825362","doi":"10.1016/j.annonc.2023.09.2066","title":"922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Plexxikon; Eisai; EMD Serono; Rakuten Medical; MacroGenics; Genentech; Coherus Biosciences; Actuate Therapeutics; Regeneron Pharmaceuticals; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Conquer Cancer Foundation; Gilead Sciences; Astellas Pharma; Celldex Therapeutics; Gateway for Cancer Research; HCA Healthcare; Pfizer","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cohort; Expanded access; Progression-free survival; Progressive disease; Head and neck cancer; Gastroenterology; Surgery; Cancer; Chemotherapy; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000319932,0.0003480532,0.001059343,0.0002036373,0.0002169526,0.0004670383,0.0002587482,0.0003561599,0.001504987],"category_scores_gemma":[0.0003374691,0.0001448034,0.000697553,0.00022103,0.0002426158,0.0003523027,0.0001369064,0.001212259,0.0003656111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006558247,"about_ca_system_score_gemma":0.0004416818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001953369,"about_ca_topic_score_gemma":0.002763484,"domain_scores_codex":[0.9998323,0.00003542703,0.000009013863,0.00003456177,0.00003024636,0.00005833086],"domain_scores_gemma":[0.9998956,0.00002096474,0.00001378586,0.00001354638,0.000009086763,0.00004707208],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3144462,0.02522583,0.0298551,0.000507571,0.001970127,0.001179515,0.0004741331,0.006349787,0.2523631,0.0003080512,0.003313806,0.3640067],"study_design_scores_gemma":[0.04143133,0.5885824,0.2512516,0.00008263085,0.004683154,0.002329213,0.0004129065,0.01029801,0.08896272,0.0003299229,0.01153142,0.0001047802],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977981,0.0009236945,0.00008338623,0.00007300923,0.00003641162,0.00006207053,0.0001127689,0.0000167669,0.0008938732],"genre_scores_gemma":[0.9985558,0.000340589,0.0001231984,0.00008578772,0.00002690577,0.00004128355,0.0002388562,0.000006312299,0.0005811836],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001953369,"threshold_uncertainty_score":0.005034685,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04322910080545783,"score_gpt":0.3161477198912267,"score_spread":0.2729186190857689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}